



# AMERICAN SOCIETY OF PLASTIC SURGEONS

## BIA-ALCL Physician Resources

## BIA-ALCL Resources

### Informed Consent Language

### **Anaplastic Large Cell Lymphoma (ALCL)**

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon type of lymphoma that can develop in the scar capsule near saline or silicone breast implants. This disease is currently being investigated as to its relationship with breast implants. The family of ALCL is a rare cancer of the immune system, which can occur anywhere in the body. Based on adverse event reports, the United States Food and Drug Administration (FDA) estimates the total number of cases of BIA-ALCL to be over 450 cases. It has been noted that the majority of BIA-ALCL patients have a history of a textured-surface device. An exact single-number estimate of the risk for both textured and non-textured implants is not possible with the currently available data. Lifetime risk of BIA-ALCL has been estimated at 1:1,000 to 1: 30,000 for women with textured breast implants, and BIA-ALCL risk is currently under investigation. BIA-ALCL usually involves swelling of the breast at an average of 3 to 14 years after the initial breast implant operation. Most cases were cured by removal of the implant and the capsule surrounding the implant; however, rare cases have required chemotherapy and/or radiation therapy for treatment.

Patients with breast implants should be followed by a surgeon over time and seek professional care for implant-related symptoms such as pain, lumps, swelling, or asymmetry. Patients should monitor their breast implants with routine breast self-exams and follow standard medical recommendations for imaging (e.g. Mammography, Ultrasound, MRI). Abnormal screening results or implant-related symptoms may result in additional expenses for tests and/or procedures to properly diagnose and treat your condition. Tests and procedures could include but may not be limited to: obtaining breast fluid or tissue for pathology and laboratory evaluation, surgery to remove the scar capsule around the breast implant, implant removal, or implant replacement.

- ▶ [BIA-ALCL Summary and Quick Facts \(08/2019\)](#)
- ▶ [BIA-ALCL By The Numbers \(08/2019\)](#)
- ▶ [Allergan Announces Worldwide Recall of Biocell Textured Implants \(07/2019\)](#)
- ▶ [BIA-ALCL Sample Letter To Patients \(07/2019\)](#)
- ▶ [BIA-ALCL Safety Advisory \(06/2019\)](#)
- ▶ [Free Educational Brochure: What Patients Need to Know \(03/2018\)](#)
- ▶ [ASPS Literature on BIA-ALCL](#)
- ▶ [ASPS Recommended Insurance Coverage Criteria for Third-Party Payers](#)
- ▶ [BIA-ALCL NCCN Guidelines \(Free Registration\)](#)
- ▶ [Free CME Class on BIA-ALCL](#)
- ▶ [Informed Consent Language \(02/2019\)](#)
- ▶ [PRS BIA-ALCL Supplement](#)
- ▶ [BIA-ALCL Patient Resources](#)